Clinical trials · Washington, D.C., DC
HIV clinical trials in Washington, D.C.
We’re tracking 70 recruiting hiv studies with a site in or near Washington, D.C. — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT06056544Enrolling by invitation
HIV prevention support for Black men who have sex with men
This study tests a personalized care coordination program to help Black men who have sex with men stay on HIV prevention. It focuses on men who are new to or have stopped PrEP and want to reduce their HIV risk.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07650916RecruitingPhase 3
A study of two ultra-long-acting HIV shots
This trial tests a new ultra-long-acting injectable combination of cabotegravir and rilpivirine for people with HIV who already have the virus under control. It aims to see if these shots can keep the virus suppressed with fewer doses.
Washington D.C., District of ColumbiaAges 12 years+ - NCT04499053RecruitingPhase 2
Durvalumab and tremelimumab with chemotherapy for advanced lung cancer in HIV
This trial tests a combination of immune therapy drugs (durvalumab and tremelimumab) given with chemotherapy in people with stage IV non-small cell lung cancer who also have HIV. It may help shrink or control cancer by boosting the immune response while keeping HIV well controlled.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04855773Recruiting
Mobile text-message support to help people stay on PrEP
This trial tests whether phone-based (iPhone/Android) text-message support can improve how consistently people use PrEP, an HIV prevention medicine. It may help you stay on track with refills and clinic visits, especially if you’re at higher risk of stopping PrEP.
Washington D.C., District of ColumbiaAges 15 years+ - NCT06691243RecruitingPhase 2
Testing semaglutide for cocaine use in adults
This study tests if the diabetes drug semaglutide (also used for weight loss) can help reduce cocaine use in adults, including those living with HIV. It's free and lasts about 8 weeks.
Washington D.C., District of ColumbiaAges 18–65 - NCT07266831RecruitingPhase 2/Phase 3
Study of islatravir and ulonivirine for new HIV patients
This trial tests two new HIV medications, islatravir and ulonivirine, in people who have never taken HIV treatment before. It aims to see if this combination can safely control the virus.
Washington D.C., District of ColumbiaAges 18 years+ - NCT01206920Recruiting
DC study following HIV prevention and care experiences over time
This study follows people who receive HIV care in Washington, DC and people using HIV prevention medicines (like PrEP) to understand health needs and outcomes over time. It may help improve how HIV care and prevention are delivered in local clinics.
Washington D.C., District of ColumbiaAges Any age - NCT00001281Recruiting
Understanding how HIV affects blood cells and body fluids
This research study examines how HIV works in the blood and body fluids of people with and without HIV. By studying blood samples, researchers hope to better understand HIV infection and develop better treatments.
Washington D.C., District of ColumbiaAges 18–120 - NCT05529342Enrolling by invitation
Long-term follow-up for a prior gene-cell treatment
This study follows people long-term after receiving a specific gene-cell treatment called AGT103-T. It helps researchers check long-term safety and outcomes, which can guide future care for others.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04949464Recruiting
Smoking quit coaching plus lung scans for people with HIV
This study tests a behavior-change program to help people with HIV quit smoking, along with routine low-dose lung CT scans to find warning signs early. It’s a feasibility study, meaning the main goal is to see if the approach is practical and acceptable, and if people can follow through.
Washington D.C., District of ColumbiaAges 45–80 - NCT07044297RecruitingPhase 3
A study of a new long-acting shot to prevent HIV
This study tests an investigational long-acting shot (MK-8527) to prevent HIV. It is for HIV-negative people who are at higher risk through anal sex without condoms, and who have not used other long-acting HIV prevention before.
Washington D.C., District of ColumbiaAges 16 years+ - NCT06872307Recruiting
Helping Black men stay on PrEP
This study tests a new way to help Black men who have sex with men stay on PrEP (HIV prevention pills) over time. If you are at risk for HIV and have stopped taking PrEP for at least a month, you may be able to join and get support to keep taking it.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06046079Recruiting
HIV Prevention Service Use Study in Washington DC
This study looks at how people in the Washington, DC area use HIV prevention services. It focuses on those who are HIV-negative and either new to PrEP, taking daily PrEP pills, or getting long-acting injectable PrEP.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05674656RecruitingPhase 1/Phase 2
Testing dolutegravir and rilpivirine in HIV-positive children
This study checks how safe and well two HIV medicines work in children ages 6 to under 12. It also measures drug levels in the body to guide dosing and watch for side effects.
Washington D.C., District of ColumbiaAges 6–12 - NCT05719441RecruitingPhase 2
Antibodies plus early HIV treatment to try for HIV remission
This study tests whether giving special HIV-fighting antibodies along with starting standard HIV medicine soon after infection can help you reach “HIV remission.” It may reduce or delay the return of detectable virus, but you must be willing to follow close monitoring and specific study steps.
Washington D.C., District of ColumbiaAges 18–70 - NCT05663502Recruiting
Donate blood and tissue samples for HIV-related cancer research
This study collects blood and tissue samples to help researchers learn more about cancers related to HIV/AIDS. You may be able to join if you’re 18+ and have HIV and a cancer diagnosis, or (if HIV-negative) a certain cancer that is closely linked to AIDS-related cancers.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06624839RecruitingPhase 2
HPV vaccine study for people with and without HIV
This study tests how well the Gardasil 9 HPV vaccine works in people assigned male at birth, including those with HIV and those taking hormone therapy. Results could help protect against HPV-related cancers.
Washington D.C., District of ColumbiaAges 18–70 - NCT06501781Recruiting
PUSH: Helping People with HIV and Substance Use
This study tests if a program that encourages positive activities (behavioral activation) can help people with HIV or on PrEP who also use substances improve their health. It focuses on those receiving long-acting injectable medications for HIV prevention or treatment.
Washington D.C., District of ColumbiaAges 18–88 - NCT06375122Recruiting
A study of Kaposi sarcoma over time
This study follows people with Kaposi sarcoma to learn more about the disease and how it changes over time. It may help doctors better understand and treat KS in the future.
Bethesda, MarylandAges 18–120 - NCT05580458RecruitingPhase 1/Phase 2
Shingles vaccine study for adults with well-controlled HIV
This Phase 1/2 study tests how safe and how well a shingles (varicella zoster) vaccine works in adults living with HIV whose immune status is measured by CD4 count, plus a healthy comparison group. It may help researchers understand whether the vaccine can safely boost protection in people with HIV.
Bethesda, MarylandAges 18 years+ - NCT00001316Recruiting
Study viral levels in blood and lymph node tissue with HIV
This study measures how much HIV is in your blood and lymph node tissue. If you qualify, you would also allow blood and other tests (including genetic and hepatitis screening), which may help researchers better understand how HIV affects the body.
Bethesda, MarylandAges 18–100 - NCT07308886RecruitingPhase 2
CYT107 for Kaposi sarcoma in HIV patients with low CD4
This trial tests an experimental drug (CYT107) that boosts the immune system to help fight Kaposi sarcoma in people with HIV who have a low CD4 count despite good HIV treatment. It aims to see if the drug can improve KS tumors and quality of life.
Bethesda, MarylandAges 18–120 - NCT06819176RecruitingPhase 1
Adding lenacapavir to disrupt HIV reservoirs in suppressed people
This trial tests whether adding a new long-acting drug, lenacapavir, to your current HIV treatment can reduce the hidden HIV that remains in your body even when standard treatment keeps the virus undetectable. The goal is to see if this can lead to better control of HIV over time.
Bethesda, MarylandAges 18–75 - NCT04902443RecruitingPhase 1
Pomalidomide plus nivolumab for virus-related cancers
This trial studies pomalidomide plus nivolumab in people with cancers linked to certain viruses (or hepatitis B/C). It may help the immune system fight the cancer when the disease has returned, progressed, or can’t be fully treated with standard options.
Bethesda, MarylandAges 18–99
Hear when a new HIV trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
HIV trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting hiv studies listed above.
- National Institutes of Health Clinical Center · 7 studies
- Whitman-Walker Health · 6 studies
- George Washington University Hospital · 3 studies
- Georgetown University Medical Center · 3 studies
- MedStar Washington Hospital Center · 3 studies
- Us Helping Us, People Into Living Inc. · 3 studies
- Baltimore Safe Haven · 2 studies
- GSK Investigational Site · 2 studies
What taking part in a hiv study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting hiv studies in District of Columbia.
Common questions
- Are there hiv clinical trials near Washington, D.C.?
- Yes. We're currently tracking 70 recruiting hiv studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a hiv study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a hiv trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New hiv studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.